SBIR/STTR Research Award

ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

Award identifier e6b7e1f7bd0985201f2b19aa9969683c62536df88ce9c25d2bf353a490d079b6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$671,659

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ASTROCYTE PHARMACEUTICALS INC.
Proposal award date
2015-09-30
Contract end date
2018-06-30
UEI
ZEP1G3FGYUP3
Solicitation number
PA14-072
Topic code
105

Research abstract

DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit neuronal damage and cell death The proprietary approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts in that it focuses on a non neuronal cell type the astrocyte which has only recently received broader attention as an important cellular target for successful therapeutic research Molecular activation of astrocytes enhances multiple healing mechanisms including protection against edema glutamate excitotoxicity and oxidative stress Preliminary data demonstrate significant neuroprotective benefits of these molecules in mouse models when administered within minutes hours and even at hours post injury The goal of this STTR Phase I project is to establish the ability of these small molecules to significantly enhance the inherent neuroprotective activity of astrocytes in both small and large animal TBI models The project aims to optimize the treatment protocol dosing timing and frequency that maximizes the in vitro neuronal viability benefits of candidate molecules utilize an in vivo mouse TBI model to select a lead candidate that maximizes reduction in the magnitude and duration of whole brain edema and reactive gliosis biomarkers and validate that the efficacy of the lead candidate in a study with a toddler piglet TBI model PUBLIC HEALTH RELEVANCE Traumatic brain injuries TBI including concussions affect million Americans annually and are the leading cause of death and disability in children and young adults Through this grant Astrocyte Pharmaceuticals aims to develop the first therapeutic for TBI patients which would limit neural damage and the associated physical cognitive and or emotional impacts of this distressingly common injury

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $5,465,311. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.